Parkinson's Foundation: Better Lives. Together.
Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

NPF and Global Kinetics Corporation Announce the Commencement of a Clinical Trial to Study Impact of Personal KinetiGraph Use in Routine Clinical Care of Patients with Parkinson's Disease

A multi-center, randomized controlled trial to assess whether the use of continuous objective measurement of changes in mobility in patients with Parkinson’s disease can improve physician treatment decisions and patient outcomes.

Melbourne, Australia & Miami, FL — Global Kinetics Corporation, developer of the Personal KinetiGraph™ (PKG™) mobile health technology for the management of patients with Parkinson’s disease and other movement disorders, and the National Parkinson Foundation (NPF) today announced a clinical research collaboration to study the impact of continuous objective measurement of movement in patients with Parkinson’s disease using the Personal KinetiGraph™ (PKG™) Movement Recording System.

Developed by Global Kinetics, the PKG™ System provides a precise, objective assessment of changes in mobility in patients with diseases and conditions that affect motor skills. The PKG™ is a wrist-worn device that automatically records motion data over a period of 6 days. Physicians can download detailed information about the patient’s symptoms within minutes, identifying changes and trends that can be important considerations in the diagnosis and treatment of Parkinson’s disease. The device can also alert patients when it’s time to take medication as prescribed and the patient can acknowledge medication taken using the device.    

This clinical research project will be a multi-center randomized controlled trial involving over 400 Parkinson’s patients conducted as part of the NPF Parkinson’s Outcomes Project Registry Study which began in 2009 as a core element of the NPF Quality Improvement Initiative. The study has grown to become an unprecedented research collaboration among over 20 leading movement disorder specialist centers and is now the largest clinical study of Parkinson’s disease with nearly 9,000 patients enrolled across four countries. “Our goal with the Parkinson’s Outcomes Project is to identify clinical practices that make a difference in patient outcomes.  The hope is that this new PKG™ study will show how we can use technology to provide information to guide better and more effective clinical decisions, helping more people with Parkinson’s to achieve the best outcomes they can, and that we will be able to translate this into other care settings,” said Peter Schmidt, PhD, NPF Senior Vice President and Chief Mission Officer.

“We are pleased that NPF have recognized the PKG as an essential tool in the management of Parkinson’s and are pleased to be able to partner with them on this clinical trial A research study in humans that aims to test a new intervention – this could be a drug, surgery or therapy like exercise or diet guidelines – to make sure it is effective and safe.. One of the great challenges in clinical care of people living with Parkinson’s disease is the subjective nature of symptom observation, which can lead to wide variability in use of medicines and in treatment protocols,” said Global Kinetics Corporation co-founder and Chief Scientific Officer, Professor and neurologist Malcolm Horne. “The PKG™ provides continuous, precise, and accurate assessments of changes in mobility in patients with Parkinson’s disease, which can play an important role in helping make informed treatment decisions, this allows clinicians to provide optimum treatment and ultimately leads to better outcomes for people with Parkinson’s.”

According to data from the NPF Parkinson’s Outcomes Project thus far, there is currently wide variability in the use of different medicines and treatment plans in Parkinson’s disease. In planning for patient care, physicians typically rely on clinical evaluation, a patient’s self-reporting of symptoms[i] and response to medication to guide therapy, potentially increasing the risk of inconsistent and diverse outcomes. “Some Parkinson’s patients are thriving, while others are not. Our goal is to determine what makes that difference. By including the PKG™ System as an element of routine care, this study will enable us to consider the interplay of continuous objective measures of patient mobility among the other factors that ultimately produce different results in different people, and likely paths toward better outcomes. Our goal is not only to optimize today’s care of Parkinson’s patients, but also to help guide tomorrow’s,” said Dr. Schmidt.

“The PKG™ System was FDA cleared in the U.S. in 2014, and many leading clinicians now have extensive experience with this technology, making this an ideal time to initiate this important clinical study,” Professor Horne said.  “This is one of several post-marketing studies currently underway with the PKG™ that will provide a wealth of new data highlighting the role that objective assessment of symptoms can play in improving patient care in Parkinson’s disease in the years ahead.”

About Parkinson’s Disease
Parkinson’s disease (PD) is a chronic, progressive movement disorder that affects the lives of at least one-half million patients in the United States[ii]. The main motor (or movement) related symptoms of Parkinson’s disease are bradykinesia Slowness of movement., rigidity, tremors and postural instability. [iii] Other non-movement symptoms include speech and swallowing difficulties, cognitive impairment, depression A mood disorder whose symptoms can include a persistent sad or empty mood, feelings of hopelessness or pessimism, irritability and loss of interest or pleasure in previously enjoyable activities. or other emotional changes. As the disease progresses, symptoms may interfere with daily activities. Parkinson’s disease can be difficult to diagnose and currently there is no cure. [iv] However, a variety of medications and surgery can help ease the symptoms for some patients.[v]  

About Global Kinetics Corporation
Global Kinetics Corporation is committed to improving the lives of those with Parkinson’s disease and other movement disorders with advanced medical technologies. The company was formed in 2007 to commercialize its lead product, the Personal KinetiGraph™ (PKG™). Developed by neurologists at the world-renowned Florey Institute of Neuroscience & Mental Health in Melbourne, Australia, the Personal KinetiGraph™ enables the precise monitoring, quantification and reporting of movement symptoms of neurological diseases. Global Kinetics Corporation, a privately held company, is headquartered in Melbourne, Australia. For more information visit:


[i] NINDS Parkinson's Disease Information Page: What is the prognosis? National Institute of Neurological Disorders and Stroke, accessed Sept. 4, 2014.  Available at:

[ii] Parkinson's Disease Research Web Overview, National Institute of Neurological Disorders and Stroke, accessed Sept. 4, 2014.  Available at:

[iii] NINDS Parkinson's Disease Information Page, National Institute of Neurological Disorders and Stroke, accessed Sept. 4, 2014.  Available at:

[iv] NINDS Parkinson's Disease Information Page: What is the prognosis? National Institute of Neurological Disorders and Stroke, accessed Sept. 4, 2014.  Available at:

[v] NINDS Parkinson's Disease Information Page: What is the prognosis? National Institute of Neurological Disorders and Stroke, accessed Sept. 4, 2014.  Available at:

Wednesday, June 22, 2016
Parkinson’s Foundation Increases Funding to $6.2 Million to Advance Parkinson’s Research
Tuesday, August 14, 2018

NEW YORK & MIAMI — August 14, 2018 — The Parkinson’s Foundation announced today an increased investment of $6.2 million across 53 research grants to support the work of promising scientists in the field of Parkinson's disease (PD) in 2018.

PD Gladiators Merges with the Parkinson’s Foundation Expanding Reach in Greater Atlanta Parkinson’s Community
Wednesday, August 1, 2018

ATLANTA – August 1, 2018—PD Gladiators, Inc., an Atlanta-based nonprofit organization focused on combatting Parkinson’s disease (PD) with vigorous exercise, has merged with the Parkinson’s Foundation (PF), a non-profit organization whose mission is to make life better for people with PD worldwide through expert care and research.

Parkinson’s Foundation Partners with Medscape Education to Deliver Patient Education
Monday, July 30, 2018

July 30, 2018—The Parkinson’s Foundation has collaborated with Medscape Education to launch an online learning program entitled “Parkinson’s Disease Psychosis: A Learning Destination for Care Partners and Patients,” available on Medscape’s patient portal, WebMD Education.

Parkinson’s Foundation Designates Three Centers of Excellence in Parkinson’s Care: Global Network Expands to 45 Parkinson’s Centers
Tuesday, July 24, 2018

MIAMI & NEW YORK CITY — July 24, 2018 — The Parkinson’s Foundation today announced the addition of three new Centers of Excellence to its global network: Cleveland Clinic; Medical University of South Carolina; and University of Iowa Hospitals and Clinics.

Parkinson’s Foundation Funds $450,000 for Local Parkinson’s Programs in Seven Cities Across the Country
Monday, July 23, 2018

NEW YORK & MIAMI — July 23, 2018 — The Parkinson's Foundation today announced it will fund nearly $450,000 to local community grants in seven cities that hosted the Foundation's annual fundraiser, Moving Day, A Walk for Parkinson's, in 2017. These grants will further the health, wellness and education of people with Parkinson's disease (PD).

In Memory of Robert Traurig
Wednesday, July 18, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member Robert (Bob) Traurig. From 2004 to 2015, he was a member of the Foundation’s board of directors. Bob is survived by his wife Jacqueline, his daughters Madeline Sackel and Wendy Traurig.

New Study Shows 1.2 Million People in the United States Estimated to be Living with Parkinson’s Disease by 2030
Tuesday, July 10, 2018

Parkinson’s Foundation Reveals Most Comprehensive Estimate of
Parkinson’s Prevalence in North America since the 1970’s

Parkinson’s Foundation Elects Howard D. Morgan Chairman of the Board
Tuesday, June 26, 2018

MIAMI & NEW YORK — June 26, 2018 — The Parkinson’s Foundation today announced the election of Howard D. Morgan as chairman of its board of directors. Mr. Morgan, who previously served as the Vice Chair of the nonprofit organization’s board, is a Partner and the Senior Managing Director of Argand Partners in New York.

Parkinson’s Foundation Announces Five New Members of its People with Parkinson’s Advisory Council
Wednesday, June 13, 2018

NEW YORK & MIAMI — June 13, 2018 — The Parkinson’s Foundation today announced five new members of its People with Parkinson’s Advisory Council.

The Parkinson’s Foundation 2018 Gala in New York City Tuesday, May 8, 2018
Monday, May 14, 2018

The Parkinson’s Foundation 2018 Gala was held at Cipriani 25 Broadway in New York City on Tuesday, May 8, 2018.


mail icon

Subscribe to get the latest news on treatments, research and other updates.